NVON
MX$1,706.27
▼-18.75%
Stock
Novo Nordisk AS
Official Company Name: Novo Nordisk A/S
Stock Symbol: NVON
Stock Market: Mexican Stock Exchange - BMV
Currency: Mexican peso - MXN
NVON Stock Price - 1 Year Price Evolution & Moving Averages
1 Year Return
▼-4.09%
Daily closing prices, with moving averages and volumes - Mexican peso (MXN)
Moving averages:
- — EMA20
- — SMA50
- — SMA200
Novo Nordisk Categories
Denmark
languages
Healthcare
languages
Biotechnology
Healthcare
Biotechnology
Company Description
Novo Nordisk is a global healthcare company involved in the research, development, manufacture, and marketing of pharmaceutical products. It operates through two segments: Diabetes and Obesity care, providing products for insulins, GLP-1, oral antidiabetic products, obesity, and other chronic diseases; and Biopharm, offering products for haemophilia, growth disorders, and hormone replacement therapy.
NVON Stock Data
| Open | MX$1,675.00 |
| High | MX$1,760.12 |
| Low | MX$1,650.40 |
| Close | MX$1,706.27 |
| Volume | 12,028 |
| Previous Close | MX$2,100.00 |
| 1-Day Change | -393.73 |
| 1-Year Change | -72.73 |
| Average Daily Volume | 852 |
| 52-Week High | MX$2,750.00 |
| 52-Week Low | MX$1,673.00 |
Disclaimer
All information and data available on Disfold is NOT FINANCIAL ADVICE. Invest at your own risk!
Past performance is not a guarantee of future performance. Patterns tend to repeat themselves, but they don't necessarily have to.
Successful backtests on past data do not guarantee the future success of the strategy backtested, especially as backtest overfitting may occur: when the price of a stock may fit particularly well a given trading strategy over a given period, but not necessarily outside of that period. Besides, backtests do not account for exact market conditions and may yield significantly different results in real trading practice (fees, slippage...).
Furthermore, even though Disfold strives to provide the best and most accurate data, errors can occur in Disfold's systems, or in our data providers' systems.
Please conduct your own due diligence to verify insights.